At the news
? NEUTRALIMPACT 3/10 PRESS-RELEASE filed Mar 13, 2026 at 08:04 ET
Purple Biotech announced that CEO Gil Efron will step down in August 2026 due to health reasons but will remain on the Board and lead corporate development. The company has initiated a search for a new CEO, emphasizing continuity in leadership and strategy around its CAPTN-3 platform.
- CEO Gil Efron will step down in August 2026 for health reasons.
- Efron will remain on the Board and lead corporate development, focusing on partnerships and financing.
- Board has started a formal search for a new CEO with biotech leadership experience.
- Efron has served as CEO since 2022 and previously as CFO; led strategic shift to CAPTN-3 platform.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access